Avalo Therapeutics, Inc. (AVTX)

Name: Avalo Therapeutics, Inc. (AVTX) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

CIK 0001534120 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Avalo Therapeutics, Inc. reported revenue of $59.0K. Revenue fell 86.6% from the prior annual period.

Key ratios (year ended 2025-12-31)

n/m

Operating margin

n/m

Net margin

-94.2%

Return on year-end equity

-86.6%

Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-10-02

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	n/a	$59.0K	$441.0K	$1.92M	$18.05M	$5.40M	$6.70M	$6.75M	$7.03M	$27.81M	$1.15M
Cost of Revenue	n/a	n/a	n/a	$1.28M	$3.43M	$1.49M	$300.0K	-$566.5K	$3.26M	$635.6K	$0
Gross Profit (computed)	n/a	n/a	n/a	$640.0K	$14.62M	$3.91M	n/a	n/a	$3.77M	n/a	n/a
R&D Expense	$64.36M	$50.08M	$24.44M	$13.78M	$31.31M	$59.84M	$32.19M	$11.76M	$5.79M	$4.37M	$10.15M
Operating Income	-$91.36M	-$72.92M	-$68.51M	-$27.35M	-$37.44M	-$82.13M	-$72.84M	-$16.14M	-$35.38M	$13.89M	-$16.08M
Depreciation & Amortization	$109.0K	$344.0K	$169.0K	$158.0K	$166.0K	$1.66M	$1.84M	$3.88M	$4.55M	$425.5K	$26.9K
EBITDA	-$91.25M	-$72.58M	-$68.34M	-$27.19M	-$37.27M	-$80.48M	-$71.00M	-$12.25M	-$30.82M	$14.32M	-$16.05M
Net Income	-$100.33M	-$78.26M	-$35.13M	-$31.54M	-$41.66M	-$84.38M	-$63.50M	-$16.07M	-$40.05M	$11.87M	-$16.47M
EPS (Diluted)	n/a	-$5.84	-$20.91	-$113.58	-$1063.00	n/a	n/a	n/a	-$1.20	$0.42	-$1.87
Total Assets	$490.78M	$116.46M	$150.73M	$20.99M	$33.37M	$80.21M	$43.76M	$36.11M	$70.25M	$42.81M	$5.77M
Total Liabilities	$42.12M	$33.41M	$17.70M	$13.69M	$44.28M	$57.13M	$19.19M	$15.11M	$49.34M	$14.95M	$5.56M
Shareholders' Equity	$448.66M	$83.05M	$133.03M	$7.30M	-$10.91M	$23.08M	$24.56M	$21.00M	$20.91M	$27.86M	$207.0K
Cash & Equivalents	$85.38M	$15.86M	$134.55M	$7.42M	$13.17M	$54.59M	$18.92M	$3.61M	$10.65M	$2.47M	$5.13M
Operating Cash Flow	-$68.29M	-$51.46M	-$49.06M	-$30.68M	-$26.75M	-$70.89M	-$40.54M	-$19.13M	-$3.13M	$12.58M	-$14.57M
Capital Expenditures	n/a	n/a	n/a	n/a	$95.0K	$113.0K	$63.0K	$262.0K	$564.4K	$23.3K	$34.9K
Free Cash Flow	n/a	n/a	n/a	n/a	-$26.85M	-$71.00M	-$40.60M	-$19.40M	-$3.69M	$12.56M	-$14.61M
Shares Outstanding	52.90M	18.51M	10.47M	801.7K	39.3K	9.40M	75.00M	44.38M	40.80M	31.27M	9.43M
Weighted Average Diluted Shares	n/a	13.40M	7.50M	277.7K	39.2K	n/a	n/a	n/a	34.77M	18.75M	8.83M
EPS (Basic)	n/a	-$5.84	-$7.94	-$113.58	-$1063.00	n/a	n/a	n/a	-$1.20	$0.42	-$1.87

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView